Lipoprotein(a), apolipoprotein(a) polymorphism and coronary artery disease severity in type 2 diabetic Tunisian population

Abid Kaouthar1*, Mili Donia1, Trabelsi Imen2, Msolli Mohamed Amine3, Nouira Semir3 and Kenani Abderraouf3

1Laboratory of biochemistry, UR 12ES08, Faculty of Medicine, Monastir, Tunisia
2Research Unit, UR 12ES09 Dyslipidemia and Atherogenesis, Faculty of Medicine, Monastir, Tunisia
3Emergency Medicine, F. Bourguiba University Hospital, Monastir, Tunisia

Abstract

Background: Lipoprotein (a) [Lp(a)] is an important genetic risk factor for coronary artery disease (CAD), but there is not enough data in the literature about the association between Lp(a) levels and the severity of CAD in diabetic patients. In addition to that, no studies considered the role of apo(a) polymorphism. The aim of this study was to investigate the association of the severity of coronary atherosclerosis with Lp(a) levels and apo(a) polymorphism in a type 2 diabetic Tunisian population.

Methods: The study population consisted of 238 consecutive type 2 diabetic patients undergoing a routine coronary angiography. The patients were subdivided into four subgroups according to the number of coronary arteries diseased: normal arteries (n = 30), single-vessels (n = 75), two-vessels (n = 55) and multi-vessels (n = 78).

Results: Lp(a) levels (normal arteries: 15.8 ± 20.1 mg/dl; mono-vessel disease: 20.1 ± 15.9 mg/dl; bi-vessel disease: 20.2 ± 15.4 mg/dl; multivessel disease: 28.3 ± 17.2 mg/dl; p < 0.001) and the percentages of patients with at least one isoform of low molecular weight (normal arteries: 25.2%; mono-vessel disease: 39.0%; bi-vessel disease: 76.8%; multi-vessel disease: 85.3%; p < 0.001) were significantly associated with increasing number of coronary vessels diseased. Multiple logistic regression analysis showed that both Lp(a) levels (OR: 1.30; 95% CI: 1.12–4.10) and apo(a) polymorphism (OR: 3.63; 95% CI: 1.78–6.45) were independent predictors of CAD severity.

Conclusions: This study demonstrated that Lp(a) levels and apo(a) polymorphism are strong predictors of CAD severity in a type 2 diabetic Tunisian population.

Introduction

Lipoprotein (a) (Lp[a]) is composed of a low-density lipoprotein (LDL) particle and a glycoprotein molecule known as apolipoprotein(a) [apo(a)] [1]. Apolipoprotein(a) is characterized by a high degree of genetic polymorphism, with many isoforms in plasma [2,3]. In advanced atherosclerosis, Lp (a) is an independent risk factor not dependent on LDL. Lp (a) represents a coagulant risk of plaque thrombosis [4]. Few studies have analyzed the possible role of apo(a) polymorphism in relation to the severity of coronary atherosclerosis [5]. Several investigations show an independent association of Lipoprotein(a), homocysteine and apo(a) polymorphism with silent CAD [6-9]. Other studies are needed to establish whether these parameters are suitable for CAD screening in diabetic patients.

The purpose of this study was to investigate the association of the severity of coronary artery disease not only with Lp(a) levels but also with apo(a) polymorphism in a type 2 diabetic Tunisian population.

Methods

Patients

The study population consisted of 238 consecutive type 2 diabetic patients undergoing a routine coronary angiography to evaluate chest pain or suspected CAD. Patients with personal history of CAD were excluded. Other exclusion criteria were: age <45 or >70 years, duration of diabetes <1 year, cardiomyopathy, heart failure, history of artery revascularization, renal insufficiency (serum creatinine ≥130 Amol/l), proteinuria, alcoholism, neoplasia, pregnancy, liver and endocrine diseases. All patients were Tunisian and gave their informed consent to participate in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Diabetic subjects were defined by a fasting plasma glucose >7.0 mmol/L, or by the use of anti-diabetic drugs [10]. Hypertension was diagnosed as a blood pressure of higher than 140/90 mmHg, which was measured according to guidelines [11] and/or the current use of anti-hypertensive drugs. Patients with albumin excretion rate (AER) <30 mg/day were considered normoalbuminuric; patients with AER between 30 and 299 mg/day were considered microalbuminuric.

Biochemical analysis

Venous blood samples were taken from subjects after fasting for...
Severity of coronary artery disease

All patients recruited in the study were subjected to coronary angiography, performed using the Sones technique with filming of multiple views of each vessel [13]. Subjects were defined with coronary artery disease (CAD) when presenting a stenosis >50% in at least one major coronary artery. Subjects were defined without coronary artery disease (No CAD) when presenting a stenosis <50% in at least one major coronary artery. The severity and the extent of coronary artery disease were evaluated with the Gensini score [14]. The Gensini score was computed by assigning a severity score to each coronary stenosis according to the degree of luminal narrowing and its geographic importance [15]. The diabetic patients were divided into four subgroups on the basis of stenotic major coronary arteries. Moreover, the results of quantitative coronary angiography have also been expressed according to the Gensini scoring system [14]. Patients with significant coronary disease were also subdivided into two subgroups with a Gensini score >40 or with a Gensini score ≤40. In patients who have undergone PTCA or aorto-coronary bypass surgery, the angiographic severity was measured before the revascularization procedures.

Statistical analysis

By using an analysis of covariance, all data regarding lipid parameters were adjusted for sex, BMI, smoking, drug intake, and presence of hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized. Hypertension, microalbuminuria and menopause. To assess differences in cholesterol, LDL, HDL, BMI, the analysis of variance was utilized.

Results

Clinical and biological features of the whole study population and of subgroups with 0, single-, two-, and multi-vessel stenosis

As shown on table 1, there is a significant linear increase in the percentages of males and subjects with a family history for CAD and in BMI. No significant differences in age, diabetes duration and glycemic control were found among the subgroups. Lp(a) levels and the percentages of patients with at least one isoform of low molecular weight (MW) were significantly correlated with increasing number of coronary vessels diseased.

Clinical and biological features of the whole study population and of diabetic patients with normal arteries, CAD patients with Gensini score <40 and those with Gensini score >40

As shown on table 2, there is a significant linear increase in the percentages of males and subjects with a family history for CAD, in cholesterol and LDL levels. No significant differences in age, diabetes duration and glycemic control were found among all the subgroups. Lp(a) levels and the percentages of patients with at least one isoform of low MW were significantly correlated with the increasing extent of the CAD.

Multivariable analysis

A multiple logistic regression analysis was performed with CAD severity (Gensini score ≤ or >40) as the dependent variable and the following as predictive variables: gender, age, family history of CAD, hypertension, diabetes duration, smoking, microalbuminuria, HbA1c, BMI, Lp(a), cholesterol, triglycerides, LDL, HDL, statin therapy. Analysis showed that BMI (OR: 2.17; 95% CI: 1.27–3.88; p = 0.04), cholesterol levels (OR: 2.52; 95% CI: 0.95–7.48; p = 0.03), Lp(a) levels (OR: 1.40; 95% CI: 0.82–4.44; p = 0.04) and family history of CAD (OR: 1.88; 95% CI: 1.20–2.16; p = 0.037) were significant predictors of CAD severity in diabetic patients. When apo(a) phenotypes (presence of at least one isoform of low MW) were added to the list of potential predictors, the analysis showed that apo(a) polymorphism (OR: 3.33; 95% CI: 1.53–6.44; p = 0.001), BMI and triglycerides were determined at accredited clinical laboratories otherwise stated. p<0.05 was considered significant.

Table 1. Clinical and biological features of the whole study population and of subgroups with 0, single-, two-, and multi-vessel stenosis

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>NO. stenosis</th>
<th>Single-vessel</th>
<th>Two-vessels</th>
<th>Multi-vessels</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>238</td>
<td>30</td>
<td>75</td>
<td>55</td>
<td>78</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>175/63</td>
<td>16/14</td>
<td>55/20</td>
<td>45/10</td>
<td>63/15</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.2 ± 6.8</td>
<td>56.1 ± 6.5</td>
<td>57.0 ± 6.7</td>
<td>59.1 ± 7.1</td>
<td>57.6 ± 6.9</td>
<td>Ns</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>28.2</td>
<td>9.5</td>
<td>15.6</td>
<td>28.9</td>
<td>44.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>44.5</td>
<td>42.9</td>
<td>32.9</td>
<td>51.7</td>
<td>48.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>BMI</td>
<td>27.1 ± 3.1</td>
<td>27.4 ± 3.5</td>
<td>26.6 ± 2.5</td>
<td>28.2 ± 2.6</td>
<td>26.5 ± 2.9</td>
<td>0.006</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>8.1 ± 5.2</td>
<td>7.6 ± 4.3</td>
<td>6.7 ± 5.2</td>
<td>9.2 ± 7.1</td>
<td>8.0 ± 5.9</td>
<td>Ns</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.3 ± 1.6</td>
<td>7.1 ± 1.1</td>
<td>7.9 ± 1.9</td>
<td>7.3 ± 1.6</td>
<td>7.3 ± 1.6</td>
<td>Ns</td>
</tr>
<tr>
<td>Microalbuminuria (%)</td>
<td>38.9</td>
<td>8.9</td>
<td>45.9</td>
<td>61.1</td>
<td>34.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>71</td>
<td>35.7</td>
<td>73.1</td>
<td>68.0</td>
<td>79.6</td>
<td>0.004</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.6 ± 1.3</td>
<td>5.1 ± 0.6</td>
<td>5.3 ± 0.8</td>
<td>6.1 ± 1.0</td>
<td>6.1 ± 1.0</td>
<td>Ns</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>4.2 ± 1</td>
<td>3.9 ± 0.9</td>
<td>3.7 ± 0.8</td>
<td>4.3 ± 0.9</td>
<td>4.3 ± 0.9</td>
<td>Ns</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>1.4 ± 0.2</td>
<td>1.1 ± 0.1</td>
<td>1.0 ± 0.2</td>
<td>1.2 ± 0.1</td>
<td>1.4 ± 0.3</td>
<td>Ns</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>2.1 ± 0.8</td>
<td>1.9 ± 0.7</td>
<td>2.3 ± 1.3</td>
<td>1.9 ± 0.8</td>
<td>2.1 ± 0.9</td>
<td>Ns</td>
</tr>
<tr>
<td>Lp(a) (mg/dl)</td>
<td>23.3 ± 17.3</td>
<td>15.8 ± 20.1</td>
<td>20.1 ± 15.9</td>
<td>20.2 ± 15.4</td>
<td>28.3 ± 17.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean</td>
<td>18.5</td>
<td>7.1</td>
<td>13.3</td>
<td>18.6</td>
<td>28.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Range</td>
<td>0.57-78</td>
<td>0.57-78</td>
<td>1.41-69</td>
<td>0.56-61</td>
<td>0.56-61.1</td>
<td>Ns</td>
</tr>
<tr>
<td>Low apo(a) phenotypes (%)</td>
<td>61.2</td>
<td>25.2</td>
<td>39.0</td>
<td>76.8</td>
<td>85.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>statins</td>
<td>35.3</td>
<td>39.0</td>
<td>36.7</td>
<td>32.6</td>
<td>30.6</td>
<td>Ns</td>
</tr>
</tbody>
</table>
(OR: 2.23; 95% CI: 1.19–4.59; p = 0.015) and cholesterol levels (OR: 2.72; 95% CI: 1.13–5.58; p = 0.039) were independent predictors of CAD severity in type 2 diabetes mellitus. Lp(a) levels (p = 0.67) and family history of CAD (0.082) are not significant.

**Discussion**

Few studies are available in the literature on the association between Lp(a) levels and the severity of coronary atherosclerosis in diabetic patients [16–18]. A study of Gazzaruso et al. shows that high Lp(a) levels and apo(a) phenotypes of low MW are associated with silent CAD not only in diabetic patients with normal ECG but also in those with ECG abnormalities [7]. Their study confirms that microalbuminuria and smoking may predict silent CAD in people with diabetes and shows an independent association between low HDL levels and silent CAD [7].

Association studies have related Lp(a) plasma levels or apo(a) isomor size (defined by immunoblotting) to the risk for CHD, myocardial infarction, stroke, or peripheral vascular disease. With only a few exceptions [19], all published retrospective case-control studies report an association of high Lp(a) with atherosclerotic vascular disease [20,21].

A previous study of Gazzaruso and al. showed that in the general population Lp(a) levels were not associated with CAD severity, while apo(a) phenotypes strongly predicted the degree of coronary atherosclerosis [5]. This study shows that both Lp(a) levels and apo(a) polymorphism are associated with CAD severity; they also found that the predictive power of apo(a) polymorphism was greater than that of Lp(a) levels. The difference in the strength of the association of Lp(a) levels with CAD extent between another study of the same team [13] and the study that we are talking about may be simply due to the fact that the first study analysed the general population, while the second one evaluated diabetic subjects.

The finding of the present study concerns the fact that in diabetic population apo(a) polymorphism is highly associated with CAD extent. The association between apo(a) polymorphism seems to be higher than that between Lp(a) levels and CAD extent. These results are in agreement with other studies analysing the general population [22, 23]. Other studies showed a growing evidence that apo(a) polymorphism is a strong predictor for CAD and that its predictive power may be greater than that of Lp(a) levels [24–26].

In conclusion, this study demonstrated that both Lp(a) levels and apo(a) phenotypes may be used not only as predictors of CAD, but also as reliable predictors of CAD severity in type 2 diabetic patients. Certainly, it is possible to suppose that diabetic subjects with a genetic predisposition to CAD due to Lp(a) and apo(a) polymorphism may have an earlier and more accelerated coronary atherosclerosis.

**References**

Lipoprotein(a), apolipoprotein(a) polymorphism and coronary artery disease severity in type 2 diabetic Tunisian population

Kaouthar A (2016) Lipoprotein(a), apolipoprotein(a) polymorphism and coronary artery disease severity in type 2 diabetic Tunisian population

Biomed Genet Genomics, 2016

16. Watts G, Gwilym RM, Mazurkiewicz J, Colard J (1995) Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care 18: 234-236. [Crossref]

Copyright: ©2016 Kaouthar A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.